NEWS Date: 2021.04.30
NEXEL Co., Ltd. signed Strategic Business Partnership Agreement with Next&Bio
- NEXEL "Cardiac Toxicity Test using hiPSC-derived cardiomyocytes"
- Next&Bio "Organoid-based New Drug Validity Screening Service"
On April 30th, NEXEL Co., Ltd. signed a MOU and a co-marketing partnership agreement with Next&Bio to develop a mutually supportive relationship.
Through this strategic business cooperation, these two companies established a foothold for building and expanding the research service market for "Cardiac toxicity test field using hiPSC-derived cardiomyocytes" and "Organoid-based new drug screening field."
NexST Cardiac Toxicity Test (NexST Cardiac Safety Service) is a cardiac safety pharmacological test service that predicts and evaluates the risks to the human heart using hiPSC-derived cardiomyocytes, which enables the development of new drugs more efficient .
NEXEL is the first company in Korea that has developed and commercialized human iPSC derived cell products for new drug toxicity test. As the only company in Korea that belongs to International Committee on Health and Environmental Sciences (HESI) research group, NEXEL is participating in the ICH guideline revision on cardiac safety pharmacology.
The two companies agreed to cooperate closely each other to establish a customized B2B business model necessary for drug discovery platform market and human tissue-based drug screening market in ther future.